Envision Pharma Group

Our latest #4Sight eBook, "The medical affairs game changer," is now available at FirstWord Pharma. Our 4Sight approach is an insights journey for medical affairs enabled by artificial intelligence (AI) as a platform. It takes a holistic view, recognizing that even the most advanced tools are only as effective as the people and processes that support them. 🔍 In this eBook you’ll discover: 💡 The right platforms to harness AI effectively 💡 Streamlined processes that lead to exceptional outcomes 💡 Essential skills for building an AI-ready team Click here to download it: https://lnkd.in/eKcjF8bZ.   #MedicalAffairs #AI #HealthcareInnovation #LifeSciences

𝗜𝘁’𝘀 𝗴𝗼 𝘁𝗶𝗺𝗲 𝘄𝗶𝘁𝗵 𝗘𝗻𝘃𝗶𝘀𝗶𝗼𝗻𝗢𝗻𝗲 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀! Discover how this new solution enables smooth and efficient data movement across Envision technology solutions and multiple data sources. Delivering actionable insights to support clinical and commercial team success will become your superpower. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗡𝗢𝗪 𝘁𝗼 𝗳𝗶𝗻𝗱 𝗼𝘂𝘁 𝗵𝗼𝘄! https://lnkd.in/g5uwpVm5 #MedicalAffairs #MedicalInformation #FutureOfHealth

What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time? In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk #CellGeneTherapy #CGT #PharmaInnovation #LifeSciences #EnvisionPharmaGroup

As an AI-enabled leader in life sciences, Envision Pharma Group is proud to be part of FutureHealth Lausanne, the premier national conference uniting top innovators in the sector. In a time where digitalization and innovation are reshaping healthcare, this event gathers the foremost leaders to explore groundbreaking solutions for more accessible and efficient healthcare in the digital age. Today, Loubna Bouarfa, one of our esteemed keynote speakers, is delivering a talk on "Innovation for health: AI-driven healthcare outcomes for all." Together with leading life sciences experts, Loubna explores the transformative potential of these disruptive key technologies.

Happy Birthday to 90TEN! As a part of Envision Pharma Group, 90TEN has been redefining healthcare communications and behavior change, delivering award-winning campaigns that inspire and make a real difference for patients, healthcare professionals, and communities. A huge thank you to the dedicated team at 90TEN for your unwavering passion and the incredible work you do every day. Your commitment to driving change and pushing the boundaries of what’s possible continues to elevate the entire Envision community. Here's to many more years of pushing boundaries and making an impact, together!

Publication bias presents an important opportunity for improvement in healthcare, particularly in enhancing the accuracy of systematic literature reviews (SLRs). In our latest blog, I explore how addressing publication bias can strengthen the evidence base, lead to more informed healthcare decisions and ensure better patient access to essential treatments.   Want to learn more?   Read the full blog to discover how to navigate the complexities of publication bias and enhance the credibility of your evidence base 👉 https://lnkd.in/eMANJVk6   #EvidenceBasedMedicine #SystematicReviews #Pharma #ValueAndAccess #MedicalWriting #ClinicalData #MarketAccess

One of our favorite moments from #Pharmageddon Europe 2024: Dr. Yahya Anvar and a remarkable panel of experts to taking on the challenge of data overload in pharma and how medical teams can leverage AI to overcome it. At Envision, we go beyond conventional solutions. As a technology-driven, AI-enabled service provider, we’re committed to delivering smarter, faster outcomes that leave a lasting impact and shape the future of healthcare. #PharmageddonEU #AIinPharma #Innovation #LifeSciences #GenerativeAI

Hello from #Pharmageddon Europe 2024! This week, Özge Özgüleryüz, Andrew Thompson, Yahya Anvar and Paul Archer are in Amsterdam collaborating with some of the boldest and most innovative thinkers from across the life sciences industry - like our friends Paul Simms and the Impatient Health team! Stay tuned for highlights. #PharmageddonEU #AIinPharma #Innovation #LifeSciences #GenerativeAI

Collaboration and strategy are the hallmarks of a successful medical affairs ecosystem, and that's what we designed the iEnvision platform to accomplish. Don't take our word for it; let the evidence speak for itself. Check out our recent case study to see how iEnvision supports a global pharmaceutical company's growing medical. affairs. https://lnkd.in/gDtEMsMg

The pharma industry is evolving, with patient perspectives rightfully gaining greater prominence. This shift is driven by the need for deeper patient insights to develop effective healthcare solutions. However, incorporating these diverse voices into value & access (V&A) strategies comes with challenges. In our latest article with Med Ad News, our Global Head of Commercial Strategy, Value & Access, Suki Kandola, explores: 💡 Empowering 'unheard' patient groups with unique insights 🌎 Navigating the evolving regulatory focus on patient-reported outcomes & real-world evidence 💪 Embracing patient-centricity to shape V&A strategies that truly resonate Learn more here: https://lnkd.in/gvBfv5hR #MarketAccess #Pharma #PatientAdvocacy